Syndax Pharmaceuticals, Inc. (SNDX)Healthcare | Biotechnology | New York, United States | NasdaqGS
13.53 USD
-0.42
(-3.011%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 13.60 +0.07 (0.517%) ⇧ (Oct. 14, 2026, 5:33 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 1:51 a.m. EDT
Syndax presents a classic biotech value trap where aggressive analyst upgrades and a 'strong buy' recommendation clash violently with deteriorating financial reality. The company is burning cash at an alarming rate, evidenced by gross margins of -8% and operating cash flow of -$220 million, while carrying a debt-to-equity ratio of nearly 4,000%. Despite a 92% revenue growth headline, the bottom line is collapsing, and the stock trades at a premium multiple of nearly 11x book value despite negative earnings. The options market confirms this skepticism; traders are buying insurance (puts) in significant quantities while waiting for a catalyst to justify the deep out-of-the-money call bets. With no dividend to cushion the fall and a balance sheet that looks increasingly fragile against its obligations, the risk-reward profile is skewed heavily against the buyer. The recent institutional buying is likely a contrarian play on a specific clinical trial outcome, but until that binary event resolves, the fundamental thesis remains broken. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.074949 |
| AutoETS | 0.074951 |
| AutoTheta | 0.075143 |
| MSTL | 0.084459 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 5.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.157 |
| Excess Kurtosis | -0.86 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3903.451 |
| Revenue per Share | 2.873 |
| Market Cap | 1,198,893,568 |
| Forward P/E | -16.12 |
| Beta | 0.42 |
| Profit Margins | -87.52% |
| Website | https://syndax.com |
As of Oct. 10, 2026, 1:51 a.m. EDT: Speculators are positioning heavily for downside protection with significant open interest in out-of-the-money puts (strikes 15, 19, 20) relative to call volume, creating a distinct 'put wall' that suggests a fear of further decline. Conversely, call activity is concentrated in deep out-of-the-money strikes (25, 28) with massive open interest, indicating speculative bets on a binary event or recovery to $25+, while near-term ATM call volume remains thin. This asymmetry reflects a market expecting volatility but leaning towards a continued struggle rather than an immediate surge.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.07247341 |
| Address1 | 730 Third Avenue |
| Address2 | 9th Floor |
| All Time High | 29.86 |
| All Time Low | 3.39 |
| Ask | 13.94 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,233,820 |
| Average Daily Volume3 Month | 1,626,857 |
| Average Volume | 1,626,857 |
| Average Volume10Days | 2,233,820 |
| Beta | 0.424 |
| Bid | 12.0 |
| Bid Size | 20 |
| Board Risk | 7 |
| Book Value | 0.169 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.53 |
| Current Ratio | 6.772 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 14.005 |
| Day Low | 13.4 |
| Debt To Equity | 3,903.451 |
| Display Name | Syndax Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,873,600 |
| Earnings Call Timestamp Start | 1,785,873,600 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | -194,160,000 |
| Ebitda Margins | -0.76971 |
| Enterprise To Ebitda | -6.597 |
| Enterprise To Revenue | 5.078 |
| Enterprise Value | 1,280,810,368 |
| Eps Current Year | -1.97534 |
| Eps Forward | -0.83912 |
| Eps Trailing Twelve Months | -2.52 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.8455 |
| Fifty Day Average Change | -5.315501 |
| Fifty Day Average Change Percent | -0.28205678 |
| Fifty Two Week Change Percent | -7.2473407 |
| Fifty Two Week High | 25.59 |
| Fifty Two Week High Change | -12.06 |
| Fifty Two Week High Change Percent | -0.47127786 |
| Fifty Two Week Low | 12.99 |
| Fifty Two Week Low Change | 0.53999996 |
| Fifty Two Week Low Change Percent | 0.041570436 |
| Fifty Two Week Range | 12.99 - 25.59 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,456,929,000,000 |
| Float Shares | 80,295,047 |
| Forward Eps | -0.83912 |
| Forward P E | -16.124035 |
| Free Cashflow | -150,078,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 298 |
| Fullday Change | -0.34999943 |
| Fullday Change Percent | -2.5089564 |
| Fullday Price | 13.6 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -0.08007 |
| Gross Profits | -20,198,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01687 |
| Held Percent Institutions | 1.26043 |
| Implied Shares Outstanding | 88,610,027 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York. |
| Long Name | Syndax Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,198,893,568 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_27240138 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -220,764,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,575,200,597 |
| Number Of Analyst Opinions | 11 |
| Open | 13.92 |
| Operating Cashflow | -220,640,000 |
| Operating Margins | -0.54947 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 781 419 1400 |
| Post Market Change | 0.07000065 |
| Post Market Change Percent | 0.5173736 |
| Post Market Price | 13.6 |
| Post Market Time | 1,792,013,593 |
| Previous Close | 13.95 |
| Price Eps Current Year | -6.8494534 |
| Price Hint | 2 |
| Price To Book | 80.05917 |
| Price To Sales Trailing12 Months | 4.75278 |
| Profit Margins | -0.87518 |
| Quick Ratio | 6.291 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.42000008 |
| Regular Market Change Percent | -3.0107534 |
| Regular Market Day High | 14.005 |
| Regular Market Day Low | 13.4 |
| Regular Market Day Range | 13.4 - 14.005 |
| Regular Market Open | 13.92 |
| Regular Market Previous Close | 13.95 |
| Regular Market Price | 13.53 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 3,038,265 |
| Return On Assets | -0.18673 |
| Return On Equity | -2.55925 |
| Revenue Growth | 0.918 |
| Revenue Per Share | 2.873 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 88,610,027 |
| Shares Percent Shares Out | 0.2042 |
| Shares Short | 18,234,880 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 21,681,907 |
| Short Name | Syndax Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.2078 |
| Short Ratio | 10.06 |
| Source Interval | 15 |
| State | NY |
| Symbol | SNDX |
| Target High Price | 57.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 37.27273 |
| Target Median Price | 37.0 |
| Total Cash | 554,265,984 |
| Total Cash Per Share | 6.207 |
| Total Debt | 589,382,016 |
| Total Revenue | 252,251,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.52 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.722124 |
| Two Hundred Day Average Change | -7.1921244 |
| Two Hundred Day Average Change Percent | -0.34707466 |
| Type Disp | Equity |
| Volume | 3,038,265 |
| Website | https://syndax.com |
| Zip | 10,017 |